Stress Urinary IncontinenceNCT03958695
A Tunable-tension Transobturator Tape vs Standard Transobturator Midurethral Tape for Stress Urinary Incontinence
A study testing Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) and Transobturator mid-urethral tape, Urosling (Lintex, LLC) in people with Stress Urinary Incontinence, run by Saint Petersburg State University, Russia at 2 sites in Russia.
Trial summary
This is the prospective randomized parallel groups trial with two participating centers (Department of Urology, Saint Petersburg State University Clinic of advanced medical technologies n.a. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Stress Urinary Incontinence
- What is being tested?
- Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) and Transobturator mid-urethral tape, Urosling (Lintex, LLC)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 320 participants
- Where
- 2 sitesRussia
- Study dates
- 1 Apr 2020to 1 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The subject is a woman with stress urinary incontinence or urodynamic mixed urinary incontinence with predominate SUI
- The subject is at least 18 years of age
- The subject has failed conservative treatment for at least 6 months
- The subject gave written consent to participate in the study,
Who cannot join
- The subject has an active urinary tract infection or skin infection in the region of surgery
- The subject has pelvic organ prolapse (POP) stage 2 or higher according to Pelvic Organ Prolapse Quantification system (POP-Q)
- The subject had prior surgery for SUI or POP
- The subject has predominate urge urinary incontinence
- The subject has a urogenital fistula, anatomical defect, stricture, diverticulum, new growth or any kind of abnormalities of the urethra
- The subject has chronic pelvic pain
Show all 13Show fewer
- The subject has a system neurological disease, such as Parkinson's disease, Alzheimer disease and other dementias, multiple sclerosis, epilepsy etc
- The subject has pelvic cancer or the subject has undergone radiotherapy for treating pelvic cancer
- The subject has post void residual (PVR) >50 ml
- The subject has dysfunctional voiding and average flow rate (Qave) < 12 ml/s
- The subject is pregnant or disagrees to abstain from the pregnancy during the study
- The subject has any mental disorders affecting his ability to evaluate the risks of the treatment and make an independent decision on participation in the study
- The subject has an allergy on local anesthetics
Trial locations and contacts
2 sites in 1 country.
Russia2 sites
Regional Clinic Hospital №3
Chelyabinsk, 454021
Saint Petersburg State University Clinic of advanced medical technologies n.a. N.I.Pirogov
Saint Petersburg, 190103
About this study
Official title: A Randomized Clinical Trial Comparing a Tunable-tension Transobturator Tape (TTT) Versus Standard Transobturator Midurethral Tape (TOT) for the Surgical Treatment of Stress Urinary Incontinence in Women
This is the prospective randomized parallel groups trial with two participating centers (Department of Urology, Saint Petersburg State University Clinic of advanced medical technologies n.a. N.I.Pirogov, Saint Petersburg, Russia; Department of Urology, Regional Hospital №3, Chelyabinsk, Russia) designed to assess the efficacy and safety of tunable-tension transobturator tape and its ability to reduce the rate of postoperative voiding dysfunction comparing to standard transobturator midurethral sling.
Read the detailed description
BACKGROUND A minimally invasive midurethral sling procedure is a favorite primary surgical method for the treatment of stress urinary incontinence (SUI). It is considered one of the most effective and safe anti-incontinence surgeries. The observed objective cure rate for transobturator sling is about 90%. However, this number may be wily because in most studies it does not exclude patients who achieved continence, but had voiding dysfunction. It is one of the most common complications of the midurethral sling, associated with the excess tape tension. The estimated rate of postoperative voiding dysfunction is up to 25%. There are few methods that allow to decrease tape tension after the surgery, such as urethral dilatation, sling mobilization, sling incision, complete excision of the tape and urethrolysis. All these methods are invasive, poorly controlled by the surgeon and are associated with the risk of recurrence of stress urinary incontinence.
PREOPERATIVE ASSESSMENT All patients who meet eligibility criteria will undergo a preoperative assessment: a detailed medical history, physical examination, vaginal examination, ICS-Uniform Cough Stress Test (ICS-UCST), uroflowmetry and ultrasound measurement of post-void residual volume (PVR). All patients will complete specific questionnaires, validated in Russia: Urogenital Distress Inventory 6 (UDI-6), International Conférence on Incontinence Questionnaire-Short Form (ICIQ-SF), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PICQ-12). The patients who will answer "Yes" to the question: "Do you experience urine leakage related to the feeling of urgency?" in UDI-6 questionnaire will undergo a urodynamic study to assess the presence and severity of detrusor overactivity.
MATERIALS AND METHODS The hypothesis is that TTT is non-inferior to TOT for SUI treatment. The sample size was calculated assuming an objective cure rate of 85% with TOT using a limit of equivalence of d=0,1 with 80% power. Thus 149 patients in each group are needed. We assume a drop-out rate of 30%, so in total 388 participants will be included in the study.
All enrolled patients will be randomly assigned to TTT or TOT treatment groups in equal ratio the day before the surgery, using computer randomization. The randomization will be performed by one resident urologist, who has no access to patients' data.
All surgical interventions will be performed by 4 urologists, performing at least 100 TOT surgeries per year. The next day after the surgery uroflowmetry values and PVR will be determined in all patients. In case of bladder outlet obstruction (BOO) symptoms, patients from TOT group will be recommended an intermittent self-catheterization for 6 weeks, or a urethral dilatation for choice. Patients from TTT group with BOO will undergo a procedure of non-invasive loosening of the tape under local anesthesia. The algorithm of uroflowmetry, PVR and tuning of the tape will be repeated until normal outflow values will be achieved. Also in patients from the TTT group, ICS-UCST will be estimated. If a patient will be experienced leakage a non-invasive tensioning of the tape under local anesthesia will be performed followed by uroflowmetry, PVR and additional tuning if necessary, until optimal tension will be achieved. The examination will be repeated on the day of discharge.
The postoperative assessment will be performed by 2 urologists, who will be blinded about the type of intervention.
- Conditions
- Stress Urinary Incontinence
- Being tested
- Tunable-tension transobturator tape, Urosling-T (Lintex, LLC), Transobturator mid-urethral tape, Urosling (Lintex, LLC)
- Keywords
- midurethral sling, stress urinary incontinence, urinary incontinence, voiding dysfunction
- Medical subject headings
- Urinary Incontinence, Stress, Urinary Incontinence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)Device
A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
Transobturator mid-urethral tape, Urosling (Lintex, LLC)Device
A transobturator tension-free mid-urethral sling
| Study group | Role | What they receive |
|---|---|---|
| Tunable-tension transobturator tape (TTT) | Active comparator | Not described Receives: Device: Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) |
| Transobturator mid-urethral tape (TOT) | Active comparator | Not described Receives: Device: Transobturator mid-urethral tape, Urosling (Lintex, LLC) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective cure of stress urinary incontinence
Objective cure is defined as the absence of urinary leakage during ICS-Uniform Cough Stress Test (ICS-UCST) in the absence of the bladder outlet obstruction
Measured: 36 months (3 years)
Secondary outcomes (7)
Observed postoperative bladder outlet obstruction
Defined as average urine flow rate <12 ml/s or/and post void residual > 50 ml or/and urine retention
Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
Subjective cure of stress urinary incontinence
Defined as an aswer "Never" to the question "Do you experience urine leakage related to physical activity, coughing or sneezing?" in UDI-6 questionnaire
Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
Observed postoperative voiding dysfunction
Defined as the presence of any of the following complaints: slow urine stream, need to strain for voiding, intermittent stream, spraying, inability to void, incomplete bladder emptying, position-dependent voiding
Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
Observed complications
Presense of any adverse effects such as: bleeding, haematoma, organ perforation, wound infection, urinary tract infection, pelvic pain, mesh extrusion in the vagina, mesh erosion into the urinary tract, dyspareunia de novo, de novo urgency
Measured: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
The assessment of the impact of treatment on the quality of life: Urogenital Distress Inventory (UDI-6) questionnaire
Measured through the Urogenital Distress Inventory (UDI-6) questionnaire, validated in Russia. The score varies from 0 to 100. The basic interpretation of the score is that the higher the score, the worse the outcome.
Measured: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)
The assessment of self-reported success of the treatment
Measured through the International Conférence on Incontinence Questionnaire Short Form (ICIQ-SF) questionnaire, validated in Russia. The questionnaire is a subjective measure of severity of urinary loss and patients' quality of life. The score varies from 0 to 21. The higher the score indicates greater severity of urinary incontinence: 1-5 - slight, 6-12 - moderate, 13-18 - severe, 19-21 - very severe.
Measured: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)
The assessment of the impact of treatment on sexual function
Measured through the scoring of Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) validated in Russia. The scale evaluates sexual function in patients with urinary incontinence and/or POP. The responses are graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Items 1 - 4 are reversely scored and a total of 48 is the maximum score. The higher scores indicate better sexual function. Up to two missing responses are accepted. The total score sum with missing values is calculated by multiplying the number of items by the mean of the responses to the items reported by that person.
Measured: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2019
- Study start1 Apr 2020
- Primary completion1 Jan 2023
- Study completion1 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stress Urinary IncontinenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 320 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saint Petersburg State University, Russia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shkarupa Dmitry, Saint Petersburg State University, Russia
- Investigators
- Dmitry Shkarupa, PhD, MD, Principal investigator, Saint Petersburg State University, Russia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03958695
- Sponsor's protocol ID
- TTTvsTOT
- Status last verified
- May 2023
- First submitted
- 5 May 2019
- Last updated
- 3 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Clinical Trial Comparing a Tunable-tension Transobturator Tape (TTT) Versus Standard Transobturator Midurethral Tape (TOT) for the Surgical Treatment of Stress Urinary Incontinence in Women
- ClinicalTrials.gov ID
- NCT03958695
- Acronym / sponsor ID
- TTTvsTOT
- Conditions
- Stress Urinary Incontinence
- Keywords
- midurethral sling, stress urinary incontinence, urinary incontinence, voiding dysfunction
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 320 participants (actual)
- Lead sponsor
- Saint Petersburg State University, RussiaUniversity, hospital or other
- Study start
- 1 Apr 2020 (actual)
- Primary completion
- 1 Jan 2023 (actual)
- Study completion
- 1 Apr 2023 (actual)
- First posted
- 22 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is the prospective randomized parallel groups trial with two participating centers (Department of Urology, Saint Petersburg State University Clinic of advanced medical technologies n.a. N.I.Pirogov, Saint Petersburg, Russia; Department of Urology, Regional Hospital №3, Chelyabinsk, Russia) designed to assess the efficacy and safety of tunable-tension transobturator tape and its ability to reduce the rate of postoperative voiding dysfunction comparing to standard transobturator midurethral sling.
Detailed description
BACKGROUND A minimally invasive midurethral sling procedure is a favorite primary surgical method for the treatment of stress urinary incontinence (SUI). It is considered one of the most effective and safe anti-incontinence surgeries. The observed objective cure rate for transobturator sling is about 90%. However, this number may be wily because in most studies it does not exclude patients who achieved continence, but had voiding dysfunction. It is one of the most common complications of the midurethral sling, associated with the excess tape tension. The estimated rate of postoperative voiding dysfunction is up to 25%. There are few methods that allow to decrease tape tension after the surgery, such as urethral dilatation, sling mobilization, sling incision, complete excision of the tape and urethrolysis. All these methods are invasive, poorly controlled by the surgeon and are associated with the risk of recurrence of stress urinary incontinence.
PREOPERATIVE ASSESSMENT All patients who meet eligibility criteria will undergo a preoperative assessment: a detailed medical history, physical examination, vaginal examination, ICS-Uniform Cough Stress Test (ICS-UCST), uroflowmetry and ultrasound measurement of post-void residual volume (PVR). All patients will complete specific questionnaires, validated in Russia: Urogenital Distress Inventory 6 (UDI-6), International Conférence on Incontinence Questionnaire-Short Form (ICIQ-SF), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PICQ-12). The patients who will answer "Yes" to the question: "Do you experience urine leakage related to the feeling of urgency?" in UDI-6 questionnaire will undergo a urodynamic study to assess the presence and severity of detrusor overactivity.
MATERIALS AND METHODS The hypothesis is that TTT is non-inferior to TOT for SUI treatment. The sample size was calculated assuming an objective cure rate of 85% with TOT using a limit of equivalence of d=0,1 with 80% power. Thus 149 patients in each group are needed. We assume a drop-out rate of 30%, so in total 388 participants will be included in the study.
All enrolled patients will be randomly assigned to TTT or TOT treatment groups in equal ratio the day before the surgery, using computer randomization. The randomization will be performed by one resident urologist, who has no access to patients' data.
All surgical interventions will be performed by 4 urologists, performing at least 100 TOT surgeries per year. The next day after the surgery uroflowmetry values and PVR will be determined in all patients. In case of bladder outlet obstruction (BOO) symptoms, patients from TOT group will be recommended an intermittent self-catheterization for 6 weeks, or a urethral dilatation for choice. Patients from TTT group with BOO will undergo a procedure of non-invasive loosening of the tape under local anesthesia. The algorithm of uroflowmetry, PVR and tuning of the tape will be repeated until normal outflow values will be achieved. Also in patients from the TTT group, ICS-UCST will be estimated. If a patient will be experienced leakage a non-invasive tensioning of the tape under local anesthesia will be performed followed by uroflowmetry, PVR and additional tuning if necessary, until optimal tension will be achieved. The examination will be repeated on the day of discharge.
The postoperative assessment will be performed by 2 urologists, who will be blinded about the type of intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tunable-tension transobturator tape (TTT) | Active comparator | Device: Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) |
| Transobturator mid-urethral tape (TOT) | Active comparator | Device: Transobturator mid-urethral tape, Urosling (Lintex, LLC) |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- The subject is a woman with stress urinary incontinence or urodynamic mixed urinary incontinence with predominate SUI
- The subject is at least 18 years of age
- The subject has failed conservative treatment for at least 6 months
- The subject gave written consent to participate in the study,
Key exclusion criteria (13 listed)
- The subject has an active urinary tract infection or skin infection in the region of surgery
- The subject has pelvic organ prolapse (POP) stage 2 or higher according to Pelvic Organ Prolapse Quantification system (POP-Q)
- The subject had prior surgery for SUI or POP
- The subject has predominate urge urinary incontinence
- The subject has a urogenital fistula, anatomical defect, stricture, diverticulum, new growth or any kind of abnormalities of the urethra
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period | Device | Tunable-tension transobturator tape (TTT) |
| Transobturator mid-urethral tape, Urosling (Lintex, LLC)A transobturator tension-free mid-urethral sling | Device | Transobturator mid-urethral tape (TOT) |
Primary outcome
Objective cure of stress urinary incontinence
Time frame: 36 months (3 years)
Objective cure is defined as the absence of urinary leakage during ICS-Uniform Cough Stress Test (ICS-UCST) in the absence of the bladder outlet obstruction
7 secondary outcomes
Observed postoperative bladder outlet obstruction
Time frame: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
Subjective cure of stress urinary incontinence
Time frame: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
Observed postoperative voiding dysfunction
Time frame: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
Observed complications
Time frame: Measured postoperatively at intervals of 1, 6, 12, 24 and 36 months postoperatively (3 years in total)
The assessment of the impact of treatment on the quality of life: Urogenital Distress Inventory (UDI-6) questionnaire
Time frame: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)
The assessment of self-reported success of the treatment
Time frame: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)
The assessment of the impact of treatment on sexual function
Time frame: Measured postoperatively at intervals of 12, 24 and 36 months postoperatively (3 years in total)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2023.
- Individual participant dataSharing planned: No
Related trials for Stress Urinary Incontinence
RecruitingPhase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Urinary Incontinence,Stress
Active, not recruitingObservational study
Return to Physical Activity After Retropublic Transvaginal Sling and Laparoscopic Sacrocolpopexy
Stress Urinary Incontinence, Pelvic Organ Prolapse
RecruitingPhase 1
Allogeneic Use of Expanded Mesenchymal Stem Cells Derived From Adipose Tissue (HC106), Female Urinary Incontinence Women Over 50 Years Old
Urinary Incontinence Stress
Recruiting
The Application of Somatosensory Interactive Pelvic Floor Muscle Training for Stress Urinary Incontinence in Men Underwent Radical Prostatectomy
Prostate Cancer (Post Prostatectomy)
RecruitingObservational study
Standardized 4D Transperineal Ultrasound Assessment of Urethrovesical Junction Mobility After Vaginal Laser Treatment for Stress Urinary Incontinence.
Urinary Incontinence , Stress, Laser Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dmitry Shkarupa, PhD, MD principal investigator
Saint Petersburg State University, Russia
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tunable-tension transobturator tape, Urosling-T (Lintex, LLC) and Transobturator mid-urethral tape, Urosling (Lintex, LLC) in people with Stress Urinary Incontinence, run by Saint Petersburg State University, Russia at 2 sites in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Objective cure of stress urinary incontinence (time frame: 36 months (3 years)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2023.